52979-42-7Relevant articles and documents
Novel vitexin-inspired scaffold against leukemia
Ling, Taotao,Lang, Walter,Feng, Xiang,Das, Sourav,Maier, Julie,Jeffries, Cynthia,Shelat, Anang,Rivas, Fatima
, p. 501 - 510 (2018/02/15)
Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children. Up to a quarter of ALL patients relapse and face poor prognosis. To identify new compound leads, we conducted a phenotypic screen using terrestrial natural product (NP) fr
2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS
-
Page 42, (2010/02/07)
Compounds of formula (I), where m, n, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor
Jaen,Laborde,Bucsh,Caprathe,Sorenson,Fergus,Spiegel,Marks,Dickerson,Davis
, p. 4439 - 4445 (2007/10/03)
The ability of a series of substituted kynurenic acids, thienopyridinonecarboxylic acids, and related compounds to inhibit the binding of nerve growth factor (NGF) to the p75 NGF receptor (NGFR) was evaluated in a radioligand binding assay that utilized a